Zhejiang Jinbikang Pharmaceutical Technology

Zhejiang Jinbikang Pharmaceutical Technology is an integrated pharmaceutical service and drug development company based in Taizhou, Zhejiang Province, China. Founded in 2022, the company operates a comprehensive business model that combines drug research and development, technical consulting, contract research organization (CRO) services, and Marketing Authorization Holder (MAH) platform operations. Zhejiang Jinbikang focuses primarily on the development and commercialization of generic and improved formulation small molecule therapeutics. Its lead pipeline program is a generic version of milnacipran hydrochloride tablets, a serotonin-norepinephrine reuptake inhibitor currently undergoing bioequivalence clinical trials in China for the treatment of depression. The company is recognized as an innovative small and medium-sized enterprise within the Taizhou Bay New Area ecosystem.